New research indicates that metformin, traditionally used for type 2 diabetes, could offer protective benefits against rejection and graft failure among kidney transplant recipients on tacrolimus, prompting calls for further investigation into its immunomodulatory effects.
Metformin, a long-established first-line treatment for type 2 diabetes, may do more than improve blood sugar in kidney transplant recipients with post-transplant diabetes mellitus. In a multicentre retrospective study published in Nature Scientific Reports, researchers followed 555 transplant patients treated between 2000 and 2018 and found that metformin use was linked with a lower risk of acute T cell-mediated rejection and graft failure among those receiving tacrolimus. The findings add to a small but growing body of evidence suggesting the drug may be safe, and possibly beneficial, in carefully selected transplant patients.
The study examined recipients according to the calcineurin inhibitor they received, splitting them into tacrolimus and cyclosporine groups before comparing outcomes by metformin exposure. After propensity score matching to reduce confounding, the protective association was clearest in the tacrolimus group, where metformin was associated with a 60% lower hazard of acute rejection and a 68% lower hazard of graft failure. Longer use also appeared to matter: patients taking metformin for more than 3.8 years showed stronger benefit. By contrast, the same pattern did not reach statistical significance in cyclosporine-treated patients, although the direction of effect was similar.
The researchers also reported no meaningful interaction between metformin use and the type of calcineurin inhibitor with respect to rejection risk, suggesting the drug’s effect may not depend strongly on whether a patient is taking tacrolimus or cyclosporine. That matters because both drugs remain central to preventing rejection after kidney transplantation, but they are also known to carry adverse effects, including hyperglycaemia, nephrotoxicity and hypertension, which can complicate post-transplant care. Earlier registry-based research has likewise suggested that metformin use in kidney transplant recipients may be associated with lower mortality and no obvious harm to graft survival.
Still, the new findings are observational, not proof that metformin directly lowers rejection risk. The authors say the results point to a possible immunomodulatory effect, but they also call for further study. That caution is important: transplant patients are complex, and treatment decisions must balance glucose control, kidney function and the risks tied to immunosuppression. Even so, the study strengthens the case for metformin as more than simply a diabetes medicine in the transplant setting.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
